ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Protopic Ointment in Adult Atopic Eczema of the Face
Phase 4
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 577
- Registration Number
- NCT00690105
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2792
- Registration Number
- NCT00688688
Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
Phase 3
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 2336
- Registration Number
- NCT00689104
A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 78
- Registration Number
- NCT00674063
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 195
- Registration Number
- NCT00673556
A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831
Phase 2
Completed
- Conditions
- Non-Alcoholic Steatohepatitis
- Interventions
- Drug: ASP9831Drug: Placebo
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2013-03-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 114
- Registration Number
- NCT00668070
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Pediatric Patients With Mild Atopic Dermatitis
Phase 4
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 426
- Registration Number
- NCT00667160
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 98
- Registration Number
- NCT00667056
Comparison Study Between Protopic (Tacrolimus Ointment) and Elidel (Pimecrolimus Cream) in Treating Pediatric Patients With Atopic Dermatitis
Phase 4
Completed
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 226
- Registration Number
- NCT00666159
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 523
- Registration Number
- NCT00666185
- Locations
- 🇿🇦
2 Sites, Port Elizabeth, South Africa
🇵🇪4 Sites, Lima, Peru
🇧🇷8 Sites, Sao Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath